AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25682543 — intervention group
Group type: EXPERIMENTAL
Intervention: PR + P (pulmonary rehabilitation plus pedometer feedback)
Number of subjects: 27
Study 25682543 — intervention group
Group type: COMPARATOR
Intervention: PR (pulmonary rehabilitation only)
Number of subjects: 27
Study 23302012 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 MAC sevoflurane
Number of subjects: 48
Study 23302012 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 MAC sevoflurane
Number of subjects: 48
Study 23302012 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 MAC sevoflurane
Number of subjects: 48
Study 23302012 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 21492750 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT (Chiropractic Manipulative Therapy)
Number of subjects: 60
Study 21492750 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT (Low-Level Laser Therapy)
Number of subjects: 60
Study 21492750 — intervention group
Group type: EXPERIMENTAL
Intervention: CMT + LLLT (Combination Therapy)
Number of subjects: 60
Study 19059939 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (as an adjunct to intensive chemotherapy)
Number of subjects: 0
Study 19059939 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy alone (control group)
Number of subjects: 0
Study 17043836 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-naive patients
Number of subjects: 184
Study 17043836 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-experienced patients
Number of subjects: 184
Study 17043836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside reverse transcriptase inhibitors resistance
Number of subjects: 184
Study 17043836 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitors resistance
Number of subjects: 184
Study 17043836 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitors resistance
Number of subjects: 184
Study 17043836 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug resistance
Number of subjects: 184
Study 12510813 — intervention group
Group type: EXPERIMENTAL
Intervention: IV neridronate (100 mg infused intravenously for 30 minutes every 3 months)
Number of subjects: 46
Study 12510813 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 46
Study 11108102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group mothers received two training sessions.
Number of subjects: 50
Study 11108102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group adolescents
Number of subjects: 50
Study 11108102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group girls
Number of subjects: 50
Study 11108102 — intervention group
Group type: COMPARATOR
Intervention: Control group mothers
Number of subjects: 50
Study 11108102 — intervention group
Group type: COMPARATOR
Intervention: Control group adolescents
Number of subjects: 50
Study 11108102 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 9344295 — intervention group
Group type: EXPERIMENTAL
Intervention: FNS ambulation training using the Parastep 1 system (32 sessions)
Number of subjects: 15
Study 7994822 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 24
Study 7994822 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 24
Study 7994822 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 24
Study 2662738 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC (30 U over 5 minutes)
Number of subjects: 231
Study 2662738 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5,000 IU in bolus injection)
Number of subjects: 231
Study 2662738 — intervention group
Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 231
Study 2662738 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 231
Study 4920226 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline for 4 days
Number of subjects: 0
Study 4920226 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulphamethoxazole for 4 days
Number of subjects: 0
Study 4920226 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol for 4 days
Number of subjects: 0
Study 4920226 — intervention group
Group type: EXPERIMENTAL
Intervention: Purging
Number of subjects: 0
Study 31991203 — intervention group
Group type: EXPERIMENTAL
Intervention: Kai-Xin-San (KXS) treatment in DPs
Number of subjects: 0
Study 31991203 — intervention group
Group type: EXPERIMENTAL
Intervention: Kai-Xin-San (KXS) treatment in CUMS rats
Number of subjects: 0
Study 31401620 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoral nerve blocks (Pecs block types I and II)
Number of subjects: 458
Study 27564322 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision mini-sling (SIMS)
Number of subjects: 100
Study 27564322 — intervention group
Group type: COMPARATOR
Intervention: Transobturator standard midurethral sling (SMUS)
Number of subjects: 100
Study 24670126 — intervention group
Group type: EXPERIMENTAL
Intervention: Home rehabilitation for mild-stroke survivors
Number of subjects: 8
Study 24670126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-stroke rehabilitation focusing on self-perceived health and self-perception
Number of subjects: 8
Study 24670126 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up in home rehabilitation services
Number of subjects: 8
Study 22457321 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix 240 mg initial dose followed by 80 mg monthly maintenance
Number of subjects: 273
Study 22457321 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix 240 mg initial dose followed by 160 mg monthly maintenance
Number of subjects: 273
Study 22457321 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 273
Study 19446342 — intervention group
Group type: EXPERIMENTAL
Intervention: Remitted major depressive disorder (rMDD) patients
Number of subjects: 0
Study 19446342 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher depressive symptom severity
Number of subjects: 0
Study 19446342 — intervention group
Group type: COMPARATOR
Intervention: General population sample
Number of subjects: 0
Study 18032763 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 353
Study 18032763 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus dexamethasone
Number of subjects: 353
Study 16126052 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 50 mcg twice daily
Number of subjects: 342
Study 16126052 — intervention group
Group type: COMPARATOR
Intervention: Montelukast (MON) 5 mg once daily
Number of subjects: 342
Study 11840031 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula with nucleotides
Number of subjects: 267
Study 11840031 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula without nucleotides
Number of subjects: 267
Study 11840031 — intervention group
Group type: COMPARATOR
Intervention: Human milk/formula-fed infants
Number of subjects: 267
Study 10068868 — intervention group
Group type: EXPERIMENTAL
Intervention: C-type natriuretic peptide (CNP) at pathophysiological plasma levels, intravenous infusion of synthetic human CNP-22 (2 pmol kg-1 min for 2 h)
Number of subjects: 6
Study 10068868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7640325 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microgram ceruletide
Number of subjects: 13
Study 7640325 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 micrograms ceruletide
Number of subjects: 13
Study 7640325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2627388 — intervention group
Group type: EXPERIMENTAL
Intervention: IV labetalol
Number of subjects: 20
Study 2627388 — intervention group
Group type: COMPARATOR
Intervention: IV hydralazine
Number of subjects: 20
Study 793680 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide and potassium chloride
Number of subjects: 0
Study 793680 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide, potassium chloride, and reserpine
Number of subjects: 0
Study 793680 — intervention group
Group type: COMPARATOR
Intervention: Potassium chloride alone
Number of subjects: 0
Study 31232712 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate therapy for 6 weeks
Number of subjects: 0
Study 31232712 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate therapy for 6 months
Number of subjects: 0
Study 31232712 — intervention group
Group type: EXPERIMENTAL
Intervention: Veverimer for 12 weeks
Number of subjects: 0
Study 31232712 — intervention group
Group type: COMPARATOR
Intervention: Veverimer
Number of subjects: 0
Study 28508185 — intervention group
Group type: EXPERIMENTAL
Intervention: AC/ixabepilone
Number of subjects: 614
Study 28508185 — intervention group
Group type: COMPARATOR
Intervention: AC/paclitaxel
Number of subjects: 614
Study 26075752 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 plus calcium
Number of subjects: 165
Study 26075752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 26075752 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 165
Study 24107876 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (100-400 mg per day)
Number of subjects: 56
Study 22036019 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg aspirin
Number of subjects: 861
Study 22036019 — intervention group
Group type: COMPARATOR
Intervention: Aspirin placebo
Number of subjects: 861
Study 22036019 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg aspirin (per-protocol analysis for 258 participants)
Number of subjects: 861
Study 22036019 — intervention group
Group type: COMPARATOR
Intervention: Aspirin placebo (per-protocol analysis for 250 participants)
Number of subjects: 861
Study 22036019 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg aspirin (per-protocol analysis)
Number of subjects: 861
Study 22036019 — intervention group
Group type: COMPARATOR
Intervention: Aspirin placebo (per-protocol analysis)
Number of subjects: 861
Study 19222314 — intervention group
Group type: EXPERIMENTAL
Intervention: Concreteness training
Number of subjects: 60
Study 19222314 — intervention group
Group type: COMPARATOR
Intervention: Bogus concreteness training
Number of subjects: 60
Study 19222314 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 60
Study 16234839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 540) received biannual individualised dietary counselling aimed at reduction of cardiovascular risk factors, especially saturated fat intake.
Number of subjects: 1062
Study 16234839 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 522) did not receive dietary counselling.
Number of subjects: 1062
Study 15669214 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin-selective reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 15669214 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin noradrenaline reuptake inhibitors (SNRIs)
Number of subjects: 0
Study 10996350 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐oestradiol and desogestrel (17betaE(2)‐D)
Number of subjects: 99
Study 10996350 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogens and norgestrel (CEE‐N)
Number of subjects: 99
Study 10996350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 9313629 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking at five different speeds
Number of subjects: 31
Study 8401618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin 800 mg at the time of anaesthetic induction
Number of subjects: 61
Study 8401618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 8401618 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 3528404 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU), doxorubicin (Adriamycin), and BCNU (FAB)
Number of subjects: 187
Study 3528404 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 187
Study 30043582 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine in addition to conventional Western medicine
Number of subjects: 88
Study 30043582 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 88
Study 27228511 — intervention group
Group type: EXPERIMENTAL
Intervention: MILD
Number of subjects: 302
Study 27228511 — intervention group
Group type: COMPARATOR
Intervention: Epidural Steroid Injections (ESIs)
Number of subjects: 302
Study 24970708 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 128
Study 24970708 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help treatment (ICBT)
Number of subjects: 128
Study 24970708 — intervention group
Group type: COMPARATOR
Intervention: Web-based discussion forum (DF)
Number of subjects: 128
Study 23427388 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) plus anti-infection and conventional medicine treatment
Number of subjects: 240
Study 23427388 — intervention group
Group type: COMPARATOR
Intervention: Anti-infection plus conventional medicine treatment
Number of subjects: 240
Study 20035541 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 88
Study 20035541 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (saphenofemoral disconnection and stripping)
Number of subjects: 88
Study 18720692 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg)
Number of subjects: 20
Study 18720692 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TAC) (20 mg)
Number of subjects: 20
Study 15771319 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 60 mg once daily
Number of subjects: 7665
Study 12819315 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programs providing individually tailored information
Number of subjects: 0
Study 12819315 — intervention group
Group type: COMPARATOR
Intervention: Educational programs providing nontailored information
Number of subjects: 0
Study 12819315 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational protocols for participant-identified providers requiring active participation
Number of subjects: 0
Study 12819315 — intervention group
Group type: COMPARATOR
Intervention: Educational protocols for participant-identified providers requiring passive participation
Number of subjects: 0
Study 10100645 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser systems (Candela, Continuum Biomedical, HGM, MDLT, SEO, Sharplan/ESC)
Number of subjects: 12
Study 8666599 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic plantar compression and aspirin
Number of subjects: 122
Study 8666599 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (Control)
Number of subjects: 122
Study 1870754 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (after conversion from cyclosporin)
Number of subjects: 34
Study 1870754 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin (control group)
Number of subjects: 34
Study 6224469 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiabendazole (50 mg kg‐1 daily for two days)
Number of subjects: 111
Study 6224469 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiabendazole (100 mg kg‐1 daily for two days)
Number of subjects: 111
Study 6224469 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (30-40 mg kg‐1 t.d.s. for three days)
Number of subjects: 111
Study 6224469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 31749064 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT)
Number of subjects: 216
Study 31749064 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 216
Study 31118080 — intervention group
Group type: EXPERIMENTAL
Intervention: External skeletal fixation (ESF)
Number of subjects: 13
Study 31118080 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking plate fixation (VLPF)
Number of subjects: 13
Study 31118080 — intervention group
Group type: COMPARATOR
Intervention: Cast fixation
Number of subjects: 13
Study 29396097 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetists aware of NIRS data
Number of subjects: 41
Study 29396097 — intervention group
Group type: COMPARATOR
Intervention: Anesthetists blinded to NIRS data
Number of subjects: 41
Study 27366132 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-30 (30 min moderate-intensity aerobic exercise)
Number of subjects: 12
Study 27366132 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-60 (60 min moderate-intensity aerobic exercise)
Number of subjects: 12
Study 27366132 — intervention group
Group type: COMPARATOR
Intervention: CON (sedentary control)
Number of subjects: 12
Study 27366132 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (EX-30, EX-60, CON)
Number of subjects: 12
Study 24930580 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 191
Study 24930580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 191
Study 24930580 — intervention group
Group type: COMPARATOR
Intervention: Perazine
Number of subjects: 191
Study 21999719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention based on self-determination theory (SDT), involving 4 meetings over 6 months with study counselors
Number of subjects: 737
Study 21999719 — intervention group
Group type: COMPARATOR
Intervention: Community care (CC) participants received smoking-cessation pamphlets and information on local treatment programs
Number of subjects: 737
Study 21999719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention based on SDT
Number of subjects: 737
Study 19843797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine 7 mg
Number of subjects: 60
Study 19843797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine 8 mg
Number of subjects: 60
Study 19843797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine 9 mg
Number of subjects: 60
Study 17204951 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (0.7 mg/kg/d)
Number of subjects: 10
Study 17204951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15501962 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin plus indomethacin
Number of subjects: 108
Study 15501962 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (control group)
Number of subjects: 108
Study 11228177 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous doxercalciferol (1alphaD(2))
Number of subjects: 70
Study 11228177 — intervention group
Group type: COMPARATOR
Intervention: Oral doxercalciferol (1alphaD(2))
Number of subjects: 70
Study 9442826 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline, 0.05% (w/v) in saline
Number of subjects: 30
Study 9442826 — intervention group
Group type: COMPARATOR
Intervention: Normal saline nasal spray (placebo)
Number of subjects: 30
Study 7931476 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) until disease progression
Number of subjects: 167
Study 7931476 — intervention group
Group type: COMPARATOR
Intervention: Observation subsequent to local treatment
Number of subjects: 167
Study 7931476 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 167
Study 7931476 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 167
Study 3495653 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula containing 1.8 g protein/100 kcal with whey/casein ratios 18:82, 34:66, or 50:50
Number of subjects: 40
Study 3495653 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 40
Study 3495653 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with reduced protein contents
Number of subjects: 40
Study 29503036 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 127
Study 29503036 — intervention group
Group type: COMPARATOR
Intervention: Loxoprofen
Number of subjects: 127
Study 27107209 — intervention group
Group type: EXPERIMENTAL
Intervention: 8IU low dose intranasal oxytocin
Number of subjects: 16
Study 27107209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Number of subjects: 16
Study 27107209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 24930697 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal (490 kcal)
Number of subjects: 30
Study 23197541 — intervention group
Group type: EXPERIMENTAL
Intervention: E-point septal separation measurements
Number of subjects: 103
Study 23197541 — intervention group
Group type: EXPERIMENTAL
Intervention: E-point septal separation as a continuous variable
Number of subjects: 103
Study 20496733 — intervention group
Group type: EXPERIMENTAL
Intervention: Long snake moxibustion combined with functional exercise
Number of subjects: 78
Study 20496733 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (oral administration)
Number of subjects: 78
Study 18005471 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.25 microg kg(‐1) min(‐1))
Number of subjects: 42
Study 18005471 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (total dose 2.6 +/- 0.3 mg)
Number of subjects: 42
Study 18005471 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 42
Study 15956292 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3-fortified process cheese (600 IU/d) for 2 months
Number of subjects: 100
Study 15956292 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2-fortified cheese (5880 IU/56.7-g serving)
Number of subjects: 100
Study 15956292 — intervention group
Group type: COMPARATOR
Intervention: Water (32,750 IU/250 mL)
Number of subjects: 100
Study 12109926 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics (specific agents not detailed)
Number of subjects: 0
Study 12109926 — intervention group
Group type: EXPERIMENTAL
Intervention: QTc-prolonging drugs
Number of subjects: 0
Study 12109926 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics with marked QTc prolongation
Number of subjects: 0